Key facts
- This page summarizes Ryan D. Maynard's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2025, 16:08.
Ryan D. Maynard - 13 Jun 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Form type
- 4
- Accepted by SEC
- 17 Jun 2025, 16:08:31 UTC
- Previous filing
- 14 Nov 2024
- Next filing
- 24 Feb 2026
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Ryan Maynard
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan D. Maynard filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 17 Jun 2025.
Change
- Previous filing in this sequence was filed on 14 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001363984
Primary reporting owner
Maynard Ryan D
- Relationship
- Director
- Address
- C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS
- Signature
- /s/ Ryan Maynard
- Signature date
- 17 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IOVA
transaction
Derivative
Deferred Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +67,546
- Change %
- Price
- $0.000000
- Shares after
- 67,546
- Date
- 13 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,546
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
Footnote F2
Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.